Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Furosemide

FDA-approved product (tablet, oral), marketed as Furoscix, Furoscix Readyflow (Autoinjector), Furosemide and 2 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Furosemide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Cirrhosis of liver
  • Congestive heart failure
  • Heart failure
  • Hypertension
  • Nephrotic syndrome
  • Pulmonary edema
  • Syndromic disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Sulfonamides, plain
FDA pharmacologic class
Loop Diuretic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA32.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli21.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae15.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Furosemide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Furosemide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Evaluation of the Efficacy of Diuretics for Symptomatic Malignant Ascites Episodes in Advanced Stage of Cancer (DIASC)

    NCT02501213 · start 2016-05-30

    Registered record
    Registry ID
    NCT02501213
    Conditions
    Cancer
    Interventions
    Spironolactone (+/- Furosemide)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2016-05-30
    Completion
    2018-12-24
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer
    InterventionSpironolactone (+/- Furosemide)
    PhasePhase 2
    Registry statusTerminated

  • AiDing Diuresis wIth Tolvaptan (ADD-IT)

    NCT02646540 · start 2016-01

    Registered record
    Registry ID
    NCT02646540
    Conditions
    Cardiomyopathy; Congestive Heart Failure
    Interventions
    Tolvaptan 30 mg + IV Diuretics; Metolazone 5 mg + IV Diuretics; 2.5 times the Diuretics Dose
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-01
    Completion
    2018-12-30
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiomyopathy; Congestive Heart Failure
    InterventionTolvaptan 30 mg + IV Diuretics; Metolazone 5 mg + IV Diuretics; 2.5 times the Diuretics Dose
    PhasePhase 1
    Registry statusCompleted

  • Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

    NCT02356159 · start 2015-09-24

    Registered record
    Registry ID
    NCT02356159
    Conditions
    Myelodysplastic Syndromes; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Acute Leukemia; Multiple Myeloma
    Interventions
    Rituximab; Conditioning chemotherapy; TMS; FLAG; EPOCH-F; Hematopoietic stem cell transplant; Palifermin; Acetaminophen; Diphenhydramine; Prednisone; Epinephrine; IV Saline; ECG; ECHO; MUGA; DEXA; CT chest; PET; MRI; BM aspirate; BM biopsy; Lumbar puncture
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2015-09-24
    Completion
    2025-03-25
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyelodysplastic Syndromes; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Acute Leukemia +1 more
    InterventionRituximab; Conditioning chemotherapy; TMS; FLAG +18 more
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Prevention of Severe Postpartum Hypertension

    NCT02450773 · start 2015-08

    Registered record
    Registry ID
    NCT02450773
    Conditions
    Hypertension
    Interventions
    Furosemide; Potassium chloride; Placebo #1; Placebo #2
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2015-08
    Completion
    2022-05
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionFurosemide; Potassium chloride; Placebo #1; Placebo #2
    PhasePhase 2
    Registry statusWithdrawn

  • Impact of Rational Control of Fluid Balance in the Intensive Care Unit

    NCT02345681 · start 2015-05

    Registered record
    Registry ID
    NCT02345681
    Conditions
    Fluid Balance of ICU Patients; Fluid Overload
    Interventions
    Furosemide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-05
    Completion
    2019-04
    Enrolment
    171

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFluid Balance of ICU Patients; Fluid Overload
    InterventionFurosemide
    PhasePhase 3
    Registry statusCompleted

  • Furosemide Stress Test as a Predictor of Tubular Function in Chronic Kidney Disease

    NCT02417883 · start 2015-04

    Registered record
    Registry ID
    NCT02417883
    Conditions
    Chronic Kidney Disease
    Interventions
    Furosemide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2015-04
    Completion
    2017-04
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Disease
    InterventionFurosemide
    PhasePhase 3
    Registry statusUnknown

  • Clinical Trial to Compare Effectiveness of Diuretics in Hemodialysis Patients With Residual Renal Function

    NCT01977430 · start 2013-11

    Registered record
    Registry ID
    NCT01977430
    Conditions
    Chronic Kidney Insufficiency; Hemodialysis Treatment; Diuresis Preserved
    Interventions
    Hydrochlorothiazide and furosemide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2013-11
    Completion
    2015-03
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Insufficiency; Hemodialysis Treatment; Diuresis Preserved
    InterventionHydrochlorothiazide and furosemide
    PhasePhase 4
    Registry statusUnknown

  • The Use of Tolvaptan to Prevent Renal Dysfunction in High Risk Patients With Heart Failure-Pilot Study

    NCT01663662 · start 2012-08

    Registered record
    Registry ID
    NCT01663662
    Conditions
    Heart Failure
    Interventions
    Tolvaptan; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2012-08
    Completion
    2013-11
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    InterventionTolvaptan; placebo
    PhasePhase 4
    Registry statusWithdrawn

  • Investigating Systemic and Local Vascular Responses to Apelin in the Context of Renin-angiotensin Upregulation

    NCT00901719 · start 2010-04

    Registered record
    Registry ID
    NCT00901719
    Conditions
    Heart Disease; Heart Failure; Vasodilatation
    Interventions
    Apelin; Acetylcholine; Sodium nitroprusside; Systemic apelin infusion
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2010-04
    Completion
    2010-05
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Disease; Heart Failure; Vasodilatation
    InterventionApelin; Acetylcholine; Sodium nitroprusside; Systemic apelin infusion
    PhaseNot applicable
    Registry statusCompleted

  • Kinetic Method to Detect Dehydration

    NCT01062776 · start 2009-10

    Registered record
    Registry ID
    NCT01062776
    Conditions
    Dehydration
    Interventions
    Dehydration; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-10
    Completion
    2010-05
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDehydration
    InterventionDehydration; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Effect of Furosemide on Obesity-induced Glomerular Hyperfiltration

    NCT00962286 · start 2009-09

    Registered record
    Registry ID
    NCT00962286
    Conditions
    Obesity-induced Hyperfiltration
    Interventions
    Furosemide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2009-09
    Completion
    2010-07
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObesity-induced Hyperfiltration
    InterventionFurosemide
    PhaseNot applicable
    Registry statusTerminated

  • Furosemide in Early Acute Kidney Injury

    NCT00978354 · start 2009-09

    Registered record
    Registry ID
    NCT00978354
    Conditions
    Acute Renal Failure
    Interventions
    Furosemide; Normal Saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Terminated
    Start
    2009-09
    Completion
    2014-07
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Renal Failure
    InterventionFurosemide; Normal Saline
    PhasePhase 2 / Phase 3
    Registry statusTerminated

  • The Effect of Continuous, Various Doses of Furosemide Drip on Hearing as Measured by Acoustic Emission

    NCT00945386 · start 2009-08

    Registered record
    Registry ID
    NCT00945386
    Conditions
    Hearing Status
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2009-08
    Completion
    2010-08
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHearing Status
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy (CIN) Prevention

    NCT00702728 · start 2008-06

    Registered record
    Registry ID
    NCT00702728
    Conditions
    Contrast Induced Nephropathy
    Interventions
    Furosemide and matched saline hydration; isotonic saline solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2008-06
    Completion
    2009-12
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionContrast Induced Nephropathy
    InterventionFurosemide and matched saline hydration; isotonic saline solution
    PhasePhase 3
    Registry statusUnknown

  • Physiopathology of Sodium Retention in Acromegaly

    NCT00531908 · start 2007-09

    Registered record
    Registry ID
    NCT00531908
    Conditions
    Acromegaly
    Interventions
    furosemide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2007-09
    Completion
    2009-12
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcromegaly
    Interventionfurosemide
    PhaseNot applicable
    Registry statusCompleted